Curocell is at the forefront of developing innovative immune cell therapies, particularly focusing on genetically modified immune cells to create advanced cancer treatments. Their proprietary OVIS™ (OVercome Immune Suppression) platform technology addresses a significant limitation in conventional CAR-T therapies, which is the exhaustion of CAR-T cells induced by immune checkpoint receptors. By merging the functions of immune checkpoint receptor blockade with CAR-T technology, Curocell's OVIS CAR-T cassette allows for the simultaneous expression of CAR and the downregulation of immune checkpoint receptors such as PD-1 and TIGIT. This strategic downregulation enhances the anti-cancer efficacy of CAR-T cells, improving their proliferation and maintaining their differentiated characteristics, which synergistically boosts their anti-tumor activity.

In addition to their innovative technology, Curocell operates a state-of-the-art GMP facility dedicated to the reliable production of next-generation cancer immunotherapies. This facility is equipped to manufacture advanced pharmaceuticals that meet stringent quality standards, ensuring that their therapies are both effective and safe for patients. Curocell's commitment to pushing the boundaries of cancer treatment through advanced immune cell therapies offers new hope to patients facing various types of cancer, as they continue to evolve their technologies to overcome existing treatment limitations.

South Korea

Curocell is a cell therapy company that discovers and develops CAR-T therapies for cancer. The company's current efforts focus on unleashing the body’s immune system through broad-spectrum CAR-T technologies to treat blood cancers, as well as solid cancers. The company's programmed T cell product candidates are differentiated by incorporation of T cell modifying technology designed to effectively overcoming the immune suppression, and thereby offers greater efficacy compared to the current CAR-T cell technology.

Curocell

Company Details